This is a clinical evidence update, not a financial catalyst. Monitor upcoming quarterly results for any acceleration in Renuvion/AYON adoption that this publication may support. No immediate trading action warranted.
Price Chart
Executive Summary
Apyx Medical announced the publication of a retrospective investigator-initiated study in *Plastic and Reconstructive Surgery - Global Open* showing that adding Renuvion (helium plasma RF) to liposuction resulted in statistically significant improvements in patient-reported satisfaction, a >50% lower abdominoplasty rate (30.0% vs. 67.1%), and lower revision rates (12.0% vs. 37.5%) with comparable complication rates. This adds clinical evidence supporting Renuvion's value proposition but does not change the company's financial outlook or near-term revenue trajectory.
Key Facts
- Study of 113 patients published in PRS Global Open evaluating Renuvion + liposuction vs. liposuction alone
- Renuvion group showed statistically higher satisfaction with reduced excess skin (BodyQ 87.8 vs. 73.8; p=0.03)
- Abdominoplasty rate was >50% lower in Renuvion group (30.0% vs. 67.1%)
- Revision rates significantly lower in Renuvion group (12.0% vs. 37.5%; p=0.038)
- Complication rates similar between groups (2.5% vs. 2.7%)
- No financial guidance, revenue figures, or material financial data provided in the filing
Financial Impact
No financial figures disclosed; clinical publication supports product differentiation but does not quantify revenue impact
Risk Factors
- Retrospective single-surgeon study design limits generalizability
- No financial data or guidance provided in the filing
- Competitive landscape in body contouring remains fragmented
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016885 |
| Exhibit: ex_962572.htm | 0001437749-26-016885 |
| Document: 0001437749-26-016885-index-headers.html | 0001437749-26-016885 |
| Document: 0001437749-26-016885-index.html | 0001437749-26-016885 |
| Document: 0001437749-26-016885.txt | 0001437749-26-016885 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $2.41 | awaiting T+20 | — | $2.43 (+0.83%) |
Aug 7, 2026 11w ago | 8-K | $3.46 $3.05 | ▼ −11.85% | ▼ −10.94% | $2.43 (−29.77%) |
May 21, 2026 22w ago | 8-K | $4.13 $3.95 | ▼ −4.36% | ▼ −2.94% | $2.43 (−41.16%) |
May 21, 2026 22w ago | Press Release | $4.25 $4.04 | ▼ −4.94% | ▼ −5.27% | $2.43 (−42.82%) |
May 14, 2026 23w ago | 8-K | $4.36 $4.69 | ▲ +7.57% | ▲ +8.43% | $2.43 (−44.27%) |
May 11, 2026 24w ago | 8-K | $3.92 $4.86 | ▲ +23.98% | ▲ +24.28% | $2.43 (−38.01%) |
Apr 23, 2026 26w ago | Press Release | $3.80 $3.79 | ▼ −0.26% | ▼ −4.90% | $2.43 (−36.05%) |
Mar 10, 2026 33w ago | Press Release | $3.45 $3.81 | ▲ +10.43% | ▲ +10.59% | $2.43 (−29.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers